Chugai ( Chugai )

Chugai

Chugai's picture

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

Chugai press release, blog etc

10/04/2017 - 21:23 Results of Preclinical Study Published in Science Translational Medicine
09/27/2017 - 00:05 Divided Granules 1.5g," a Photodynamic Diagnostic Agent Obtained Manufacture and Marketing Approval
08/25/2017 - 00:07 Both are Designated Intractable Diseases
08/24/2017 - 00:52 Chugais Emicizumab Receives Priority Review Designation by FDA
08/22/2017 - 21:27 New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab
07/31/2017 - 12:23 Chugai and National Cancer Center Japan
07/27/2017 - 17:25 Judgment Rendered on the Suit for Damages with Regard to the Process Patent Infringement for OXAROL Ointment
06/29/2017 - 03:12 Chugais Deputy Chairman Motoo Ueno as
06/27/2017 - 02:46 Chugai to Sponsor 2017 Wheelchair Softball Tournament in Tokyo
06/26/2017 - 02:35 Chugais Bispecific Antibody Emicizumab to Present
06/26/2017 - 02:27 Approval of Additional Dosage for Actemra
06/06/2017 - 02:10 Data of Chugai's Alecensa Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
06/01/2017 - 02:10 Contribution of Funds to the Second Phase of
05/11/2017 - 01:58 Results of the J-ALEX Study for Chugai's Alecensa are Published in The Lancet Online
05/10/2017 - 02:20 Update on Phase III study of Immune Checkpoint Inhibitor
05/10/2017 - 02:08 Chugai Enters into a License Agreement for Emicizumab with JW Pharmaceutical
05/04/2017 - 04:09 Announcement of a Lawsuit Filed against Chugai
04/30/2017 - 02:46 Notice regarding Issuance of New Shares as Restricted Stock Compensation Plan